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Sleep disorders are prevalent in Alzheimer's disease (AD) and a major cause of institutionalization. Like
AD pathology, sleep abnormalities can appear years before cognitive decline and may be predictive of
dementia. A bidirectional relationship between sleep and amyloid β (Aβ) has been well established with
disturbed sleep and increased wakefulness leading to increased Aβ production and decreased Aβ clear-
ance; whereas Aβ deposition is associated with increased wakefulness and sleep disturbances. Aβ ﬂuc-
tuates with the sleep-wake cycle and is higher during wakefulness and lower during sleep. This ﬂuc-
tuation is lost with Aβ deposition, likely due to its sequestration into amyloid plaques. As such, Aβ is
believed to play a signiﬁcant role in the development of sleep disturbances in the preclinical and clinical
phases of AD. In addition to Aβ, the inﬂuence of tau AD pathology is likely important to the sleep dis-
turbances observed in AD. Abnormal tau is the earliest observable AD-like pathology in the brain with
abnormal tau phosphorylation in many sleep regulating regions such as the locus coeruleus, dorsal ra-
phe, tuberomammillary nucleus, parabrachial nucleus, and basal forebrain prior to the appearance of
amyloid or cortical tau pathology. Furthermore, human tau mouse models exhibit AD-like sleep dis-
turbances and sleep changes are common in other tauopathies including frontotemporal dementia and
progressive supranuclear palsy. Together these observations suggest that tau pathology can induce sleep
disturbances and may play a large role in the sleep disruption seen in AD. To elucidate the relationship
between sleep and AD it will be necessary to not only understand the role of amyloid but also tau and
how these two pathologies, together with comorbid pathology such as alpha-synuclein, interact and
affect sleep regulation in the brain.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
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For over 25 years, a high prevalence of sleep disorders has been
identiﬁed in patients with Alzheimer's disease (AD). Many studies
have estimated that 25–66% of AD patients exhibit sleep disorders
of some kind and sleep disturbances are one of the leading causes
of AD patient institutionalization (Bianchetti et al., 1995; Guarnieri
et al., 2012; Moran et al., 2005). Sleep is an important biological
function and although sleep disturbances were once considered to
be a bi-product of neurodegeneration, they are not limited to ad-
vanced disease states but occur even before cognitive decline and
may be predictive of neurodegeneration (Hahn et al., 2013; Lim
et al., 2013). AD pathology has been shown to begin long before
the onset of the clinical cognitive impairment characteristic of AD.
The preclinical stage of AD is characterized by the aggregation of
amyloid-β (Aβ) peptide into amyloid plaques in the brain and a
decrease of Aβ42 in the cerebrospinal ﬂuid (CSF) as well as tau
phosphorylation and aggregation into neuroﬁbrillary tangles (NFT)
and neuropil threads in neocortical regions (Holtzman et al., 2011).
This molecular pathology, especially tau pathology, is then linked
with neuronal death, synaptic loss, cognitive impairment, and AD
diagnosis (Jack and Holtzman, 2013; Holtzman et al., 2011). The
presence of sleep disturbances throughout preclinical and clinical
disease progression underscores the important role sleep may play
in disease pathology and progression.
Studies in humans and mouse models have begun to unravel
the relationship between sleep, AD, and cognitive impairment, but
much work remains. Due to the abundance of mouse models that
develop amyloid deposition and biomarker tests available, much is
known about the bidirectional interaction between sleep, Aβ, and
its aggregation in the brain. However, to fully understand the in-
teraction between AD and sleep, the contribution of tau and other
pathologies cannot be ignored. Here, we will review the clinical
relationship between AD and sleep and how amyloid pathology
contributes to this interaction. We will further highlight how tau
pathology in AD may interact with sleep disturbances including
evidence from tauopathies such as frontotemporal dementia
(FTD). Lastly, up to 60% of AD patients also have the presence of
alpha-synuclein aggregation in the brain and we will highlight
ways in which this pathology may contribute to sleep disturbances
seen in AD as well as similarities between AD and dementia with
Lewy bodies (DLB)(Hamilton, 2000).2. Sleep and circadian disturbances in AD patients
AD patients exhibit a wide array of sleep, electro-
encephalography (EEG), and circadian dysfunction that is well
reviewed in the literature (Musiek et al., 2015; Peter-Derex et al.,
2015; Lim et al., 2014b). Excessive daytime sleepiness (EDS), sun-
downing, and insomnia are among the most common reported
disturbances in AD and stem from changes in sleep architecture
and circadian rhythm. AD patients have been shown to have de-
creased sleep efﬁciency, non-rapid eye movement (NREM) sleep
and slow wave sleep (SWS) as well as decreased rapid eyethis article as: Holth, J.K., et al., Sleep in Alzheimer's Diseas
p://dx.doi.org/10.1016/j.nbscr.2016.08.002imovement (REM) sleep and increased latency to REM sleep (Vi-
tiello et al., 1990; Bliwise et al., 1989; Bonanni et al., 2005). Con-
sequently, AD patients display an increase in wakefulness that is
characterized by an increased number of awakenings at night
(Moe et al., 1995; Vitiello et al., 1990; Bonanni et al., 2005). Taken
together these changes result in an observed increase in sleep
fragmentation in AD patients (Vitiello et al., 1990). Sleep dis-
turbances are found to occur throughout clinical disease with most
changes visible in mild disease stages and these disruptions wor-
sen with disease severity (Vitiello et al., 1990; Bonanni et al., 2005;
Liguori et al., 2014b). Increased REM sleep latency and wakefulness
as well as decreased REM sleep and sleep efﬁciency are also found
to correlate with impaired cognitive function (Moe et al., 1995;
Liguori et al., 2014b). The abundance of sleep disturbances in AD
patients even in early stages of cognitive impairment may be due
to neuronal and synaptic loss that is already occurring at these
stages of disease.
Prior to clinical diagnosis, sleep disturbances are also a risk
factor for developing cognitive dysfunction and AD. A recent study
in a preclinical population has shown using actigraphy that a de-
crease in sleep efﬁciency is visible even in cognitively normal
people that are amyloid positive compared to those that are
amyloid negative, suggesting a role for Aβ aggregation in pre-
clinical sleep changes (Ju et al., 2013). Furthermore, clinical follow
up studies have shown that cognitively normal older individuals
with high sleep fragmentation had a 1.5-fold increased risk of
developing AD and self-reported reduced sleep was associated
with a 2-fold increased risk of AD development (Hahn et al., 2013;
Lim et al., 2013). These early, preclinical changes in sleep suggest
that poor sleep may be a risk factor and biomarker for AD and
cognitive decline and demonstrates that pathological AD-type
changes may be leading to sleep abnormalities prior to obvious
cognitive symptoms. This supports the idea that sleep disruption
may be prognostic for future cognitive decline.
Changes in sleep architecture are also accompanied by changes
in EEG power. Quantitative EEG studies show that AD patients
exhibit EEG slowing in both wake and REM sleep that increases
with disease severity and suggest that REM sleep EEG slowing is a
robust biomarker for AD severity (see (Petit et al., 2004) for in-
depth review). Markers of circadian dysfunction have also been
identiﬁed in AD patients and include increased nocturnal activity,
decreased diurnal activity, core body temperature phase delay and
amplitude decrease, clock gene phase changes across brain re-
gions, and changes in sleep regulating hormones such as de-
creased nocturnal melatonin (sleep promoting) and increased
hypocretin/orexin (wake promoting) (Volicer et al., 2001; Harper
et al., 2005; Liguori et al., 2014b; Wu et al., 2003; Cermakian et al.,
2011). The relationship between AD progression and sleep mod-
ulating hormones is not straightforward however. Studies have
shown that CSF orexin levels in moderate to severe AD are sig-
niﬁcantly increased compared to controls and high orexin levels
were appropriately associated with increased nocturnal dis-
turbance (Liguori et al., 2014b). However, post mortem analysis
shows decreased hypocretin in the CSF and a 40% reduction in
hypocretin 1 immunoreactive neurons in the hypothalamuse–Beyond Amyloid. Neurobiology of Sleep and Circadian Rhythms
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AD pathology, and neurodegeneration (Fronczek et al., 2012).
The exact cause of sleep and circadian changes in AD is un-
known but likely stems from pathology induced breakdown in
crucial sleep regulating areas and pathways in the brain. Sleep
centers are located throughout the basal forebrain, hypothalamus,
thalamus, midbrain, pons, and brainstem, areas that can be af-
fected by AD pathology. Changes may also result from loss of
speciﬁc neuronal populations important to sleep regulation. A
recent study showed loss of galanin positive neurons in the ven-
trolateral preoptic (VLPO)/intermediate nucleus in AD patients and
less galanin neurons correlated with increased sleep fragmenta-
tion (Lim et al., 2014a). VLPO galanin neurons are sleep active,
inhibit wake-promoting neurons, and loss of these neurons is a
possible mechanism for decreased NREM sleep and increased
awakenings in AD (Saper et al., 2005). Loss of cholinergic neurons
in the basal forebrain (BF) or noradrenergic neurons in the locus
coeruleus (LC) in AD could also not only affect cognition but sleep-
wake regulation as well (Iraizoz et al., 1999; Rogers et al., 1985;
Brunnström et al., 2011; Wilson et al., 2013). Scattered AD pa-
thology in the suprachiasmatic nucleus (SCN) has also been es-
tablished and this circadian rhythm ‘pacemaker’ of the brain de-
generates in AD (Stopa et al., 1999). The loss of vasopressin and
neurotensin positive neurons in the SCN is also correlated with
increased activity rhythm fragmentation and increased nocturnal
activity, respectively (Harper et al., 2008; Stopa et al., 1999). These
observations demonstrate a direct relationship between AD pa-
thology and sleep degeneration.3. Amyloid and sleep
Aβ aggregation begins early during preclinical, or pre-sympto-
matic AD (Jack and Holtzman, 2013; Holtzman et al., 2011). Simi-
larly, sleep changes can begin early in AD and be predictive of
neurodegeneration or increase risk of developing cognitive decline
in AD. As such, Aβ has so far been a focus in AD sleep research
which is aided by the availability of many animal models that
overexpress and develop Aβ pathology.
3.1. Amyloid-precursor protein (APP)/Aβ overproduction induces
sleep changes in animal models
APP/Aβ overproduction models recapitulate many of the sleep
changes observed in AD patients and provide a unique opportunity
to explore the direct effect of APP/Aβ on sleep without the pre-
sence of other pathological characteristics of AD such as tau ag-
gregation. Increases in wake and decreases in both NREM and REM
sleep have been reported in most mouse models studied including
APP/PS1, 5x FAD, PDAPP, TgCRND8, and Tg2576, similar to changes
seen in AD patients (Roh et al., 2012; Schneider et al., 2014; Hui-
trón-Reséndiz et al., 2002; Colby-Milley et al., 2015; Zhang et al.,
2005). The normalization of these deﬁcits by Aβ immunization in
APP/PS1 and Tg2576 mice demonstrates the ability of Aβ pathology
itself (distinct from APP) to induce changes in sleep architecture
(Wisor et al., 2005; Roh et al., 2012). Furthermore, APP transgenic
mice have increased sleep fragmentation, increased latency to
REM sleep, and decreased number of REM sleep bouts, changes
that are reminiscent of those seen in clinical AD (Colby-Milley
et al., 2015; Sethi et al., 2015; Zhang et al., 2005). Sleep changes in
multiple models have also been shown to occur early in disease
progression when plaque pathology is low and worsen with age,
exemplifying the importance of Aβ aggregation on sleep disruption
in early and advanced stages of AD (Colby-Milley et al., 2015;
Huitrón-Reséndiz et al., 2002; Zhang et al., 2005). The effects of Aβ
on sleep are not limited to mice and humans, but extend toPlease cite this article as: Holth, J.K., et al., Sleep in Alzheimer's Diseas
(2016), http://dx.doi.org/10.1016/j.nbscr.2016.08.002iDrosophila, where expressing Aβ results in decreased and frag-
mented sleep (Tabuchi et al., 2015). These studies across organisms
demonstrate the importance and robust effect of amyloid pathol-
ogy on sleep. EEG power also appears to be affected in most mouse
models. Despite differences between models, there is a prevailing
observation of decreased power with disease progression in the
delta and/or theta frequencies (Colby-Milley et al., 2015; Zhang
et al., 2005; Schneider et al., 2014). Furthermore, unlike humans
with AD who display EEG showing, these mouse models show an
increase in higher EEG frequencies, demonstrating that Aβ mouse
models do not recapitulate all aspects of sleep changes seen in
clinical AD (Colby-Milley et al., 2015; Zhang et al., 2005).
The ability of amyloid pathology to induce many changes si-
milar to that seen in AD suggests that amyloid may be a driving
force behind sleep changes in early AD and throughout disease
progression. How Aβ induces sleep changes is still to be de-
termined and is likely the result of many mechanisms. Changes
could be due to the effect of Aβ and amyloid pathology on neu-
ronal populations or brain regions crucial to sleep-wake systems.
Although amyloid pathology in the subcortical and brainstem
nuclei is shown to occur later in disease and cannot explain early
changes in sleep (Serrano-Pozo et al., 2011), worsening of sleep
deﬁcits may be due to progression of pathology spreading from
cortical to subcortical and later brainstem structures, as suggested
in the CRND8 mouse model (Colby-Milley et al., 2015). In AD brain,
diffuse plaques are found throughout the hypothalamus, which
contains many sleep regulating regions including the VLPO, the
main sleep promoting region of the brain where NFTs are in-
frequent, and amyloid pathology in this region is one possible
mechanism for the sleep loss observed in AD (Standaert et al.,
1991). Amyloid plaques are also the dominant clinical AD pathol-
ogy observed in the periaqueductal grey matter (PAG), with 81% of
AD cases having amyloid pathology in this dopaminergic wake-
active area, although tau pathology is observed early in disease
progression as well (Parvizi et al., 2000; Stratmann et al., 2016).
Sleep changes could also be the result of neuronal circuit dys-
function, such as Aβ induced breakdown of slow oscillations and
coherence in the neocortex, thalamus and hippocampus and de-
terioration of slow-wave activity (Busche et al., 2015). These are
but a few of the possible mechanisms by which Aβ may induce
changes in sleep.
3.2. The bidirectional relationship between Aβ and sleep disturbance
In addition to AD patients and APP/Aβ overexpressing animal
models exhibiting sleep disturbances it has been well documented
that sleep disruption can alter soluble Aβ levels acutely and Aβ
deposition chronically, thus demonstrating a bidirectional re-
lationship between Aβ and sleep (see (Ju et al., 2014) for in depth
review). In imaging studies in adults without cognitive decline,
sleep disruptions such as shorter sleep time, decreased sleep ef-
ﬁciency, and increased latency to sleep are shown to be associated
with Aβ deposition in the brain (Ju et al., 2013; Brown et al., 2016;
Branger et al., 2016; Spira et al., 2013). Furthermore, SWS arousals
are correlated with Aβ42 levels in humans with mild cognitive
impairment but not controls (Sanchez-Espinosa et al., 2014). The
importance of sleep in amyloid AD pathogenesis has been further
elucidated in sleep deprivation studies in humans and animal
models. A single night of sleep deprivation in healthy young adults
signiﬁcantly increased morning Aβ42 levels (Ooms et al., 2014).
Sleep deprivation in Aβ overexpressing mice also induced an in-
crease of monomeric Aβ acutely in the brain (Kang et al., 2009).
Over time, sleep deprivation induced monomeric Aβ increase can
have a dramatic disease promoting effect. This was demonstrated
in the Tg2576 and APP/PS1 amyloid mouse models which both had
a signiﬁcant increase in amyloid plaque pathology followinge–Beyond Amyloid. Neurobiology of Sleep and Circadian Rhythms
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8 weeks of increased sleep by treatment with an orexin receptor
antagonist signiﬁcantly decreased amyloid pathology in APP/PS1
mice, suggesting that sleep is a potent modulator of amyloid both
acutely, of monomeric Aβ, and over time, of amyloid pathology
progression (Kang et al., 2009). Drosophila that overexpress Aβ
demonstrate the same increase in Aβ accumulation with sleep
deprivation and decrease in accumulation with sleep increase,
further supporting the strong effect of sleep on amyloid pathology
(Tabuchi et al., 2015).
Increases in Aβ due to sleep disturbance could be the result of
increased Aβ secretion, decreased clearance, or both mechanisms.
In Drosophila, sleep deprivation induced Aβ increases are lost
when neuronal hyperexcitability is inhibited, suggesting that Aβ
increases with sleep deprivation are due to increased neuronal
activity that accompanies wakefulness (Tabuchi et al., 2015). This
observation is supported in mice where both sleep deprivation
and neuronal activity increases Aβ secretion into the interstitial
ﬂuid (ISF) (Cirrito et al., 2005; Kang et al., 2009). Sleep has also
been shown to facilitate clearance of Aβ from the ISF by means of
the glymphatic system, and thus the decrease of clearance in this
fashion may also contribute to the increases in Aβ when sleep is
lost (Xie et al., 2013).
3.3. Amyloid-β and circadian rhythm
Circadian dysfunction is well documented in AD patients and
studies have demonstrated a delicate interaction between AD,
circadian function, and amyloid (see (Musiek et al., 2015) for in
depth review). Aβ, like many proteins in the brain, exhibits a cir-
cadian ﬂuctuation and this observation is seen in both humans
and mice. Humans have increased CSF Aβ throughout the daytime
that then decreases at night and these Aβ levels are inversely
correlated with sleep (Huang et al., 2012). Mouse ISF Aβ exhibits
the same circadian ﬂuctuation in both wild type and APP/Aβ
overexpression models (Roh et al., 2012; Kang et al., 2009). The
ability of sleep deprivation to raise Aβ levels in the brain could be a
direct result of this ﬂuctuation. Lack of sleep may inhibit the re-
duction of Aβ that would normally occur during the restful period,
which could affect amyloid pathology development in AD over a
longer period of time. Furthermore, AD pathology affects this Aβ
ﬂuctuation. In humans, the amplitude of Aβ ﬂuctuation decreases
both with age as well as the presence of amyloid aggregation and
amyloid positive patients with familial dominant AD have a loss of
Aβ ﬂuctuation (Roh et al., 2012; Huang et al., 2012). Lower CSF Aβ42
levels in humans is also associated with lower hypocretin levels
and increased amyloid pathology, further suggesting the im-
portant relationship between abnormal circadian function and AD
amyloid pathology (Slats et al., 2012). Aβ overexpressing APP/PS1
mice display a similar loss of circadian Aβ ﬂuctuation in the ISF,
likely due to sequestration of Aβ42 into amyloid plaques, a phe-
nomenon also likely occurring in humans (Roh et al., 2012). The
loss of ﬂuctuation occurs with the onset of amyloid pathology and
is rescued by Aβ42 immunization, demonstrating the causative role
of amyloid pathology in the loss of Aβ ﬂuctuation (Roh et al., 2012).
In addition to Aβ ﬂuctuation, amyloid overexpression mouse
models also show changes in circadian processes such as de-
creased thermoregulation and increased period, suggesting that
some form of Aβ is sufﬁcient to induce circadian dysregulation
similar to that seen in ageing and AD (Wisor et al., 2005; Huitrón-
Reséndiz et al., 2002; Song et al., 2015). Mechanistically, APP/Aβ
overexpression may affect circadian features through SCN degen-
eration, which is observed in 3xTg mice and humans with AD
(Sterniczuk et al., 2010; Harper et al., 2008). Although rare, diffuse
amyloid plaques are seen in the SCN of AD patients (Stopa et al.,
1999). Aβ in culture and mouse models is also shown to inducePlease cite this article as: Holth, J.K., et al., Sleep in Alzheimer's Diseas
(2016), http://dx.doi.org/10.1016/j.nbscr.2016.08.002ichanges in clock genes, such as decreases in PER2 and BMAL1,
which could induce circadian dysregulation outside the SCN (Song
et al., 2015). Taken together, these studies demonstrate an im-
portant interaction between Aβ and circadian rhythms that could
contribute to and possibly accelerate disease progression.4. Tau and sleep
The hyperphosphorylation and intercellular aggregation of tau
protein is the second hallmark of AD and unlike Aβ, total and
phosphorylated tau in the CSF has been shown to predict and
correlate with cognitive decline in preclinical and clinical AD
(Fagan et al., 2007; Mattsson et al., 2009). Furthermore, tau pa-
thology has recently been shown to be the earliest observable AD-
like change in human brain, with abnormal tau phosphorylation
and aggregation in the LC beginning as early as young adulthood
and extending to other connected regions even before amyloid is
detected (Braak et al., 2011; Stratmann et al., 2016). Despite these
observations, very little is known about the effect of tau pathology
on sleep in preclinical or clinical AD. Currently, our understanding
of the possible role of tau in AD related sleep disturbance is based
off the presence of NFTs in sleep centers of the brain, limited
studies in AD mouse models containing both APP and tau trans-
genes or a human tau transgene alone, and what is known about
sleep in other tauopathies such as FTD. Together, these areas
highlight the important role tau may play in sleep dysregulation in
AD.
4.1. Neuroﬁbrillary tangles in sleep, wake, and circadian centers of
the brain during AD pathogenesis
Sleep-wake cycles are tightly regulated in the brain by many
brain regions, neurotransmitters, and ﬂip-ﬂop switches. Sleep
regulating areas are found throughout the brain including the
brainstem, midbrain, thalamus, hypothalamus, and BF (Fig. 1)
(Saper et al., 2005). These many regions regulate arousal (as-
cending arousal pathway), promote and inhibit NREM and REM
sleep, as well as regulate circadian rhythms and the biological
clock (Fig. 1). Many of these regions, especially the wake-pro-
moting arousal system, are shown to be affected by abnormal tau
pathology in the human brain with many of the changes occurring
during pretangle stages or stage 0 of tau pathology by Braak and
Braak staging, prior to any cortical tau or amyloid pathology de-
velopment (Fig. 1) (Braak et al., 2011; Stratmann et al., 2016; Stern
and Naidoo, 2015; Braak and Del Tredici, 2011). Here we will dis-
cuss sleep, wake, and circadian regulating areas of the brain
known to be affected by tau pathology to underscore the potential
importance of tau in sleep dysregulation.
4.1.1. Ascending arousal system
The ascending arousal system is composed of wake-active
neuronal groups and includes many brain areas known to contain
abnormal tau phosphorylation pathology early in life and with AD
disease progression (Stern and Naidoo, 2015; Braak et al., 2011;
Braak and Del Tredici, 2011). Tau pathology ﬁrst appears in the
brainstem LC and extends to the medial parabrachial nucleus
(mPB), the dorsal raphe (DR), and the PAG (Braak et al., 2011;
Stratmann et al., 2016; Braak and Del Tredici, 2011). Pretangle tau
pathology is also found in the hypothalamic tuberomammilary
nucleus (TMN), lateral hypothalamus (LH), and the BF (Braak et al.,
2011; Stratmann et al., 2016; Braak and Del Tredici, 2011) (Fig. 1).
All of these areas have abnormal tau phosphorylation prior to
cortical tau or amyloid pathology and may play a role in tau in-
duced sleep dysregulation during normal aging (Braak et al., 2011;
Stratmann et al., 2016; Braak and Del Tredici, 2011). In AD, manye–Beyond Amyloid. Neurobiology of Sleep and Circadian Rhythms
Fig. 1. Schematic of tau pathology in sleep, wake, and circadian brain regions and pathways. The ascending arousal system (blue) leading to cortical arousal is composed of
brain regions active in wake (blue circles) or both wake and REM sleep (blue stars). Many of these regions are shown to be affected by abnormal tau pathology in pretangle
stages, prior to cortical tau or Aβ pathology (pink outline) or in clinical AD (purple outline), suggesting a role for tau in sleep-wake dysregulation in aging and AD. The
hypothalamic VLPO (orange square) sleep generating region inhibits wake active areas of the ascending arousal system (orange dash). However, the VLPO as well as the
circadian master clock SCN (brown triangle) have not been shown to have signiﬁcant tau pathology (no outline) in AD. The REM sleep producing SLD (green), which interacts
with the REM-off ventrolateral PAG, and NREM/SWS generating PFZ (light purple) have not yet been studied for the presence of tau pathology (yellow outline) but could play
a role in sleep loss seen in AD. Adapted by permission from Macmillan Publishers Ltd: Neuron (Saper et al., 2005).
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lopontine tegmental nucleus (PPT) and laterodorsal tegmental
nucleus (LDT), have been shown to have robust NFT pathology,
further supporting a role of tau in AD sleep disturbances (Fig. 1)
(Parvizi et al., 2001; Stern and Naidoo, 2015).
Noradrenergic wake-active neurons in the LC play an excitatory
role in the ascending arousal system of the cortex and inhibit the
sleep producing VLPO neurons (Fig. 1) (Saper et al., 2005; Stern
and Naidoo, 2015). Braak et al. demonstrate that abnormal tau
species are found in this area in a high percentage of young adults
(70% at 20 years of age) prior to cortical tau or amyloid burden
(Braak et al., 2011). Furthermore, NFTs in the LC are reproducibly
found in AD patients as well as cognitively normal and mildly
impaired adults without full blown dementia (Grudzien et al.,
2007; Dugger et al., 2012). In AD, LC noradrenergic neurons are
lost and LC neuron number is found to be correlated to cognitive
decline in a non-demented cohort (Wilson et al., 2013; Brunn-
ström et al., 2011). Increased NFTs in the LC is also related to more
rapid cognitive decline (Wilson et al., 2013). NFTs in and loss of LC
neurons may therefore be playing a role in sleep disturbances and
EDS found in preclinical and early AD (Stern and Naidoo, 2015). In
addition to AD pathology driving loss of LC neurons, these neurons
are also susceptible to increased wakefulness (Zhang et al., 2014).Please cite this article as: Holth, J.K., et al., Sleep in Alzheimer's Diseas
(2016), http://dx.doi.org/10.1016/j.nbscr.2016.08.002iSince increased wake is characteristic of AD, it follows that AD may
be able to induce degeneration of this area, further contributing to
disease and sleep dysfunction. Lastly, LC degeneration has been
shown to promote Aβ pathology in APP23 mice and result in in-
creased neuronal loss and memory deﬁcits (Heneka et al., 2006).
Tau pathology in the LC or wake induced neuronal loss could
therefore affect amyloid pathology development and disease
progression in AD. Taken together, tau pathology in the LC may
have a profound effect on both sleep and cognition in AD patho-
genesis and begin years before other pathologies are present,
making it an important area for study of the interaction between
sleep, tau, and AD. Furthermore, early pathology in the LC alone is
not recapitulated, to our knowledge, in any AD or human tau
(htau) mouse models. Such models would be invaluable in
studying this interaction.
The serotonergic neurons of the DR are also wake active and in
addition to pretangle stage detection of tau pathology in this re-
gion, NFT pathology in the DR was also identiﬁed in preclinical AD
patients (stage 0, 1 and 2) as well as those with a clinical AD di-
agnosis (Saper et al., 2005; Stern and Naidoo, 2015; Chen et al.,
2000; Stratmann et al., 2016; Rüb et al., 2000; Grinberg et al.,
2009). Beyond the presence of NFTs in the DR, neuron density is
also decreased in AD patients (Chen et al., 2000). Although thise–Beyond Amyloid. Neurobiology of Sleep and Circadian Rhythms
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correlated with cognitive decline, it is possible that loss of ser-
otinergic neurons and NFT induced changes in this region con-
tributes to sleep dysregulation in AD patients (Chen et al., 2000).
The mPB is also wake active and inhibited by the parafacial zone
(PFZ) during NREM sleep (Anaclet et al., 2014). Abnormal tau pa-
thology in the mPB was identiﬁed at stage 0 and NFTs are found in
the mPB of up to 91% of postmortem clinical AD brains in the
absence of amyloid pathology, supporting a link between clinical
symptoms and tau pathology in this region (German et al., 1987;
Parvizi et al., 2001; Stratmann et al., 2016).
Cholinergic neurons in the PPT and LTD are active during wake
and REM sleep (Fig. 1) (Stern and Naidoo, 2015; Saper et al., 2005).
Although studies of stage 0 AD tau pathology have not reported
early tau pathology in these areas, NFTs are common in the LDT
and PPT in clinical AD (Dugger et al., 2011; Dugger et al., 2012;
Parvizi et al., 2001). One study showed that 69% of AD postmortem
brains contained NFTs in the PPT without amyloid pathology
present there, even in patients with short disease duration (Parvizi
et al., 2001). Furthermore, 66% of patients had NFT pathology in
the LDT and the presence of NFTs in this area correlated with
disease progression (Parvizi et al., 2001). The wake-active, REM-
inhibiting PAG of the midbrain has Stage 0 development of tau
pathology (Stratmann et al., 2016). However, in the PAG one study
reported that only 9% of clinical AD brains autopsied had NFT
pathology, while 81% contained amyloid plaques (Parvizi et al.,
2000). Therefore the effect of NFTs in this area is unclear.
In the hypothalamus, abnormal tau pathology is present in the
pretangle, precortical tau stage in the TMN and LH (Fig. 1) (Strat-
mann et al., 2016). Furthermore, in patients who died with de-
mentia due to AD, hypothalamic NFTs are numerous and con-
centrated in the TMN and accompanied by wake-active histami-
nergic neuronal loss (Nakamura et al., 1993; Airaksinen et al.,
1991a; Stern and Naidoo, 2015; Standaert et al., 1991). This focus of
pathology suggests a role of tau in neuronal loss in the TMN and a
possible contribution to sleep disruption, but the inﬂuence of
amyloid cannot be ignored since diffuse amyloid plaques are also
present throughout the hypothalamus in the AD brain (Standaert
et al., 1991). Although most prominent in the TMN, NFTs can also
be seen in the LH in clinical AD (Standaert et al., 1991). LH neurons
are wake active and produce orexin, which acts to stabilize the
sleep-wake switch, allowing for sustained arousal and sleep (Saper
et al., 2005). Pretangle tau pathology has also been reported spe-
ciﬁcally in the prefornical area which contains the orexinergic
neurons (Stratmann et al., 2016). Although it is not known if tau
pathology affects orexinergic neurons, orexin is an important
marker of sleep-wake regulation that is shown to increase in the
CSF of moderate to severe AD patients and is positively correlated
to total tau and related to sleep impairment in AD (Liguori et al.,
2014b). Furthermore, orexin levels in cognitively normal elderly
correlate with phosphorylated tau, suggesting that tau could be a
driving factor in orexin and wakefulness changes in the brain
(Osorio et al., 2016).
Tau pathology also reaches the magnocellular nuclei of the BF
in pre-tangle stages of AD development, mild cognitive impair-
ment, and early AD, as well as in cognitively normal age matched
controls (Braak et al., 2011; Mesulam et al., 2004; Stratmann et al.,
2016; Iraizoz et al., 1999). Cholinergic neurons in the basal fore-
brain (nucleus basalis of Meynert (NBM)) are active during wake
and REM sleep and also play an important role in cognition with
excitatory projection to the cortex (Fig. 1) (Saper et al., 2005; Stern
and Naidoo, 2015). NBM neurons are lost in AD and cell number
decreases with disease progression (Rogers et al., 1985; Iraizoz
et al., 1999). NFTs may be to blame for this cell loss since remaining
neurons in this area contain NFTs but very few, if any, amyloid
plaques are present (Iraizoz et al., 1999; Rogers et al., 1985).Please cite this article as: Holth, J.K., et al., Sleep in Alzheimer's Diseas
(2016), http://dx.doi.org/10.1016/j.nbscr.2016.08.002iFurthermore, NFTs in the NBM correlate with higher mental de-
terioration and decreased BF volume in AD correlates with in-
creased cortical amyloid plaque burden, suggesting that tau pa-
thology and loss of neurons in the BF could play a role in disease
progression as well as cognitive decline and sleep disruption
(Kerbler et al., 2015; Iraizoz et al., 1999).
Many regions of the ascending arousal system are affected by
tau pathology early in life and prior to preclinical amyloid pa-
thology development, supporting that tau may play a crucial role
in sleep disturbance and sleep-wake system dysregulation not
only in clinical AD but also in preclinical AD and normal aging.
More work is needed to determine if tau pathology in these areas
induces changes in sleep-wake regulation. It is known that lesions
in some of the wake regulating areas discussed here do not induce
changes in sleep-wake architecture (Fuller et al., 2011; Gompf
et al., 2010). However, tau pathology may induce dysregulation by
affecting multiple areas, speciﬁc cell types, or in conjunction with
pathology in sleep promoting regions.
4.1.2. Sleep promoting regions
AD pathology in and degeneration of sleep promoting regions
of the brain could explain the loss of sleep seen in clinical AD. One
of the main sleep promoting regions of the brain is the VLPO. The
VLPO, located in the hypothalamus, projects to the ascending
arousal system and inhibits this system during sleep (Fig. 1) (Saper
et al., 2005). Surprisingly, the VLPO has not been shown to contain
prominent NFT pathology (Standaert et al., 1991). However, there
are other regions in the brain that function to generate NREM and
REM sleep, such as the PFZ and the sublaterodorsal area (SLD),
which may be affected by tau pathology (Fig. 1). The PFZ, a group
of GABAergic neurons in the brainstem, is a SWS generating region
recently identiﬁed in mice (Anaclet et al., 2014). Disruption of the
PFZ could result in decreased SWS as seen in AD, but to our
knowledge pathology in this region remains unstudied (Anaclet
et al., 2014). The SLD and pre coeruleus is a REM generating region
in the brain also elucidated in mice and rats (Krenzer et al., 2011;
Lu et al., 2006). The presence of tau pathology in the SLD has not
been speciﬁcally studied. However, the SLD REM producing region
is located near the LC, the earliest location of tau pathology, so it is
possible that tau pathology could accumulate in this region
throughout aging and the progression of AD. Furthermore, the SLD
receives input from the ventrolateral PAG which serves as a REM
off region. The PAG has also been shown to have early presence of
tau pathology, strengthening the possible effect of tau on REM
sleep (Krenzer et al., 2011; Lu et al., 2006). Disruption to or cell loss
in the SLD or disruption of the REM on/off balance could be a
possible mechanism for loss of REM sleep and increased REM la-
tency in AD. Other brain areas that are active in wake are also
active during REM sleep and affected by tau pathology in pre-
tangle stages, the BF, and in clinical AD, the LDT and PPT (Fig. 1).
Degeneration in these regions could further decrease REM sleep
pathway activation and sustenance.
4.1.3. Circadian regions
The SCN is the master pacemaker of the body and regulates
circadian rhythm and inputs (Fig. 1). There is not signiﬁcant tau
pathology in this region with only scattered NFTs as well as rare,
diffuse amyloid plaques observed in the SCN of AD brains (Stopa
et al., 1999). Although the impact of this pathology on circadian
rhythm is unknown it may contribute to the loss of vasopressin
and neurotensin neurons in the SCN and circadian disruption ob-
served in AD patients (Musiek et al., 2015; Stopa et al., 1999). The
TMN has also been shown to project to the SCN and contain tau
pathology which could possibly affect input and regulation of the
SCN circadian clock (Stern and Naidoo, 2015; Airaksinen et al.,
1991b; Braak et al., 2011; Standaert et al., 1991). More work ise–Beyond Amyloid. Neurobiology of Sleep and Circadian Rhythms
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regulated in a circadian fashion to determine if there is a tau/cir-
cadian interaction.
4.2. Sleep changes in htau expressing mice
Mice expressing human tau transgenes with disease promoting
mutations that cause FTD have been studied in recent years, but
only a small number of sleep studies in these mice have been
conducted to assess the ability of tau pathology to induce sleep
disruption. In an effort to model AD, mice containing both amyloid
pathology and human forms of tau have been studied. Circadian
changes reminiscent of AD have been noted in the 3xTg mouse
model, which has decreased vasopressin neurons in the SCN, in-
creased daytime activity, and shorter circadian period (Sterniczuk
et al., 2010). This demonstrates that tau and Aβ pathology, either
alone or together, can induce circadian changes. A second amyloid
and tau model, PLB1, has shown changes in sleep architecture si-
milar to AD patients and Aβ-depositing mice including increased
wake, decreased NREM and REM sleep, less frequent and shorter
REM bouts, increased number of short NREM bouts, and overall
sleep fragmentation that worsens with age (Jyoti et al., 2015; Platt
et al., 2011). This model was further analyzed for the effect of the
htau P301L transgene alone by extraction of the amyloid pathology
producing portion of the transgene (Koss et al., 2016). Analysis of
PLB1Tau mice demonstrated for the ﬁrst time that forebrain mutant
htau expression alone alters sleep. Speciﬁcally, PLB1Tau mice have
increased wake and decreased NREM sleep, as well as more robust
changes in EEG power than observed in PLB1 mice with both tau
and amyloid (Koss et al., 2016). This work is the ﬁrst evidence that
tau pathology alone can induce sleep changes reminiscent of
neurodegenerative disease. However, more work is needed in this
model to determine what brain regions tau pathology accumulates
in as well as other tau models to understand how tau may be
inducing changes in sleep. Lastly, loss of tau in tau knock out mice
induces changes in sleep including increased wake, decreased
NREM sleep, and sleep fragmentation, demonstrating that en-
dogenous tau function is important to sleep regulation and loss of
tau function in tauopathies like AD, not just tau pathology, could
contribute to the sleep changes observed (Cantero et al., 2010).
Tau may not only affect sleep and wake parameters but it is
possible that sleep disruption could contribute to tau pathology
progression, as seen with Aβ. One study in 3xTg mice showed an
increase in insoluble tau and MC1 staining for conformational tau
changes following 2 months of sleep deprivation by light cycle
manipulation (Di Meco et al., 2014). This suggests a possible bi-
directional relationship between tau pathology and sleep, similar
to that seen with Aβ, which could accelerate disease progression.
However, this model also includes APP/Aβ overexpression so the
effect of amyloid in the observed changes cannot be ignored (Di
Meco et al., 2014). Neuronal activity has also been shown to in-
crease tau in the ISF, raising the possibility for extended wake-
fulness to impact tau pathology progression (Yamada et al., 2014).
Although much work remains, these studies demonstrate that tau
may be an important component of sleep-wake dysregulation in
the development of AD and needs to be taken into consideration
when dissecting and understanding the cause and effect of sleep
changes in AD.
4.3. Sleep disturbances in tauopathies
The FTD spectrum includes multiple disorders, many of which
contain tau pathology. Tau aggregation occurs in approximately
half of the patients with behavioral variant FTD (bvFTD), which
affects the frontal and temporal lobe, and 70% of nonﬂuent/
agrammatic variant FTD cases, which affects the posterior frontalPlease cite this article as: Holth, J.K., et al., Sleep in Alzheimer's Diseas
(2016), http://dx.doi.org/10.1016/j.nbscr.2016.08.002ilobe and insula (Pressman and Miller, 2014; Pan and Chen, 2013).
There are also 2 other pure tauopathies: progressive supranuclear
palsy (PSP) and corticobasal degeneration (CBD) (Pan and Chen,
2013). PSP is characterized by globose NFTs that affect largely the
brainstem and basal ganglia while CBD is characterized by bal-
looned neurites, globose corticobasal bodies, and ﬁne ﬁlamentous
inclusions in the cortex as well as the basal ganglia, subcortical
nuclei, and brainstem (Dickson, 1999; Pan and Chen, 2013). In both
of these disorders, there are also astrocytic tau inclusions (Dickson,
1999). Despite the variation in FTD, studies have shown that pa-
tients suffer from sleep disturbances as frequently as or possibly
more than AD. One large clinical study showed that 65.7% of AD
patients and 76% of FTD patients had sleep disturbances of some
kind including insomnia, restless leg syndrome, sleep disordered
breathing, and EDS (Guarnieri et al., 2012). This and other studies
suggest that sleep is possibly better preserved in AD than FTD
(Bonakis et al., 2014; Guarnieri et al., 2012; Pistacchi et al., 2014).
FTD patients experience many similar sleep disturbances as AD.
Studies in bvFTD patients have shown decreased total sleep time
and percent sleep, decreased sleep efﬁciency that is worse in MRI
abnormal FTD, decreased REM sleep, and changes in NREM sleep
(Anderson et al., 2009; Bonakis et al., 2014). When compared to
AD patients, there are no striking differences in bvFTD patient
sleep parameters. One study showed no differences in any sleep
parameters between AD and bvFTD and while a second showed
AD and bv-FTD to both display EDS and altered NREM sleep
compared to controls, only the NREM/REM ratio was signiﬁcantly
decreased in FTD compared to AD, although REM sleep and total
sleep were decreased in FTD only compared to controls (Bonakis
et al., 2014; Kundermann et al., 2011). Finally, when analyzing
orexin, no difference has been observed between FTD and controls
but FTD orexin levels are decreased compared to AD (Çoban et al.,
2013; Liguori et al., 2014a).
Studies in pure tauopathies have also shown these patients to
exhibit sleep disturbances similar to those in AD. Patients with PSP
have decreased total sleep time and sleep efﬁciency, decreased
sleep spindles, increased sleep latency, and decreased REM sleep
characterized by decreased number and duration of REM episodes
(Gama et al., 2010; Montplaisir et al., 1997; Petit et al., 2004). The
observed changes in REM sleep in PSP are suggestive of PPT de-
generation (Montplaisir et al., 1997). As previously discussed, the
PPT contains robust tau pathology in AD, and thus tau pathology in
this brain region may contribute to the loss of REM sleep in AD.
Furthermore, PSP exhibits slowing of wake EEG as well as EDS that
correlates with disease progression, similar to changes observed in
AD (Montplaisir et al., 1997; Gama et al., 2010; Petit et al., 2004). A
patient with a TAU G389R mutation causing tau pathology and
hereditary Pick's disease also showed sleep fragmentation and
decreased SWS (Gemignani et al., 2005). These observations de-
monstrate the ability of tau pathology to induce profound changes
in sleep not unlike those seen in AD and supports a possible role
for tau pathology in AD sleep disruption.5. Alpha-synuclein aggregation, DLB, and sleep
Alpha-synuclein is a 140 amino acid protein predominantly
expressed at pre-synaptic terminals of neurons and is thought to
play a role in vesicle trafﬁcking and release (Bendor et al., 2013).
Intracytoplasmic aggregates of alpha-synuclein, present in Lewy
bodies and Lewy neurites, are pathological hallmarks of a group of
neurodegenerative diseases such as Parkinson disease, multiple
system atrophy, and DLB. Up to 60% of patients with sporadic AD
also have Lewy body pathology in the brain (Hamilton, 2000). AD
cases with Lewy bodies show pathology consistently in the
amygdala but this can also be observed to spread through thee–Beyond Amyloid. Neurobiology of Sleep and Circadian Rhythms
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ment (Hamilton, 2000). Dominantly inherited AD patients also
have a high prevalence of Lewy bodies in the brain that are con-
centrated in the amygdala but also found in limbic, neocortical,
and brainstem regions (Lippa et al., 1998; Leverenz et al., 2006).
Dominantly inherited AD patients with Lewy bodies outside of the
amygdala also had a longer course of disease (Leverenz et al.,
2006). Furthermore, there is some overlap in symptoms and pa-
thology of AD and DLB which makes it worthwhile to examine the
relationship between DLB and sleep here (McKeith, 2000; Lippa
and Knopman, 2007; McKeith et al., 2005).
DLB is characterized by the onset of dementia like symptoms,
cognitive dysfunction and visual hallucinations coincident with
Parkinsonism. In addition to the brain stem and striatum, DLB
features synuclein deposits in the insula, cingulate cortex, amyg-
dala and hippocampus (Dickson et al., 1994; Tsuboi and Dickson,
2005; Harding and Halliday, 2001; Bertrand et al., 2004; Aarsland
et al., 2004). DLB cases can further present with extensive Aβ de-
posits in the striatum (Serrano-Pozo et al., 2011). Parkinson's dis-
ease with dementia is similar to DLB except that Parkinsonism
precedes cognitive impairment by at least one year and usually
longer. A number of sleep disorders present along with DLB and
some reports estimate that 50% of DLB patients have sleep dis-
orders and this can increase to over 70% in moderate to severe
disease (Borroni et al., 2008; Farina et al., 2009). When compared
to AD, it has also been suggested that DLB has an overall greater
sleep disturbance with DLB patients exhibiting twice as many
nocturnal sleep disturbances as AD (Grace et al., 2000; Bliwise
et al., 2011). There is also some evidence to suggest measurable
changes in sleep characteristics in DLB patients. Although research
is limited, one study reported decreased stage 1 NREM sleep and
increased stage 2 NREM sleep in DLB patients when compared
with Parkinson disease patients (Terzaghi et al., 2013). Quantita-
tive EEG studies in DLB have further reported EEG slowing as well
as high variation and ﬂuctuation of mean EEG power in wake
(Petit et al., 2004; Walker et al., 2000). There is evidence of ac-
cumulation of synuclein pathology in the form of Lewy bodies in
wake active neurons of various brain regions (LH, LC, TMN, NBM,
DR) which could contribute to the sleep disorders and dis-
turbances observed in DLB (Stern and Naidoo, 2015). Furthermore,
like in AD and other neurodegenerative disorders, DLB patients
show underlying circadian dysregulation. One study suggests that
DLB patients have greater disruption in locomotor activity than AD
patients and non-demented controls with signiﬁcantly decreased
diurnal activity (Harper et al., 2004). DLB also trended towards
increased nocturnal activity compared to controls but remained
less than AD (Harper et al., 2004). Temperature circadian phase
occurred signiﬁcantly later in both AD and DLB, although DLB
patients showed lower core-body temperature amplitude than AD
and was not signiﬁcantly different from non-demented controls
(Harper et al., 2004).
Outside of these generalized sleep and circadian disturbances,
DLB is characterized by several speciﬁc sleep conditions that also
aid in differentiating it from AD and other dementias including
REM sleep behavior disorder (RBD), EDS, and periodic limb
movement disorder (PLMD) (Borroni et al., 2008; Farina et al.,
2009). RBD, a condition where patients physically ‘act out’ their
vivid dreams during REM sleep, is now considered a part of the
diagnostic criteria for DLB (Boeve et al., 1998; Iranzo et al., 2014;
Ferman et al., 2011; McKeith et al., 2005). In fact, RBD can precede
any dementia-like symptoms and can be considered to be the
prodromal phase of DLB (Boeve et al., 2013; Donaghy and McKeith,
2014). Multiple longitudinal studies tracking frequency and
emergence of neurodegenerative symptoms in patients diagnosed
with RBD have found that a large portion of these patients go on to
develop Parkinsonism or dementia. About 30–40% of patients werePlease cite this article as: Holth, J.K., et al., Sleep in Alzheimer's Diseas
(2016), http://dx.doi.org/10.1016/j.nbscr.2016.08.002ifound to have Parkinsonism or dementia within 5 years of an RBD
diagnosis and about 80% of RBD patients develop Parkinsonism or
dementia within 12 years (Boeve et al., 2013; Schenck et al., 1996;
Schenck et al., 2013; Postuma et al., 2009; Iranzo et al., 2006,
2013). Both LBD and RBD have been associated with loss of cho-
linergic neurons in the brain stem including the LC, PPT/LDT and
substantia nigra (Dugger et al., 2012; Uchiyama et al., 1995). One
study in dementia patients found that patients with DLB are much
more likely to have RBD than patients with AD (Boeve et al., 2001).
Although RBD is a not a common feature of AD, it is interesting to
note that patients with AD do show loss of neurons in LC and tau
pathology is present in the PPT and LDT (Dugger et al., 2011;
Brunnström et al., 2011; Parvizi et al., 2001). PLMD is more com-
monly associated with restless leg syndrome in PD, but is also
found separately in patients with DLB (Fantini et al., 2002). A study
comparing patients with AD and DLB found a higher frequency of
PLMD in DLB patients (Hibi et al., 2012). A lot remains unknown
about PLMD, such as its etiology, true prevalence, and mechanism.
EDS is another sleep condition that although prevalent in AD, is
shown to be more frequent in DLB (Boddy et al., 2007). As the
name suggests, patients with EDS have difﬁculty maintaining
wakefulness during the day. Like RBD, EDS is more prevalent in
patients with DLB than AD as measured and conﬁrmed by poly-
somnography and multiple sleep latency test (Boddy et al., 2007;
Ferman et al., 2011). Although the mechanism(s) underlying EDS is
not completely clear, there are some indications that orexinergic
neurons in the lateral hypothalamus are lost in both DLB and AD,
which might contribute to EDS in both diseases (Fronczek et al.,
2007; Fronczek et al., 2012; Lessig et al., 2010). Furthermore, or-
exinergic neurons modulate the sleep-wake switch by virtue of
their reciprocal actions on ascending arousal wakefulness neurons,
many of which are known to be affected by AD and DLB pathology
and could contribute to sleep disturbances in both diseases (Saper
et al., 2010).6. Conclusion
Sleep disturbances are prevalent in AD and may play a sig-
niﬁcant role in the advancement of pathology and disease pro-
gression. Although Aβ and amyloid pathology has been established
to interact with sleep and circadian rhythms, tau pathology and
also the co-morbidity of alpha-synuclein aggregation may be im-
portant contributors to sleep system dysfunction in AD. Tau pa-
thology in the brainstem is the earliest AD-like pathological
change that occurs during normal aging and abnormal tau pa-
thology is present in many sleep centers of the brain even before
the onset of amyloid pathology. Early studies in an htau expressing
mouse model shows sleep disturbances with tau pathology alone.
These observations combined with the high prevalence of sleep
disorders in other tauopathies exempliﬁes the need to understand
the interaction between tau and sleep in addition to and in con-
junction with Aβ pathology.Acknowledgments
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